Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Q1 FY27 Earnings Presentation
18 slides from Gland Pharma's earnings presentation, Aug 10, 2026
Slide 1: Cover letter to stock exchanges: Investor Presentation on Q1FY27 Results
GLAND PHARMA LIMITED August August 10, 10, 2026 2026 BSE Limited BSE Limited National National Stock Stock Exchange Exchange of of India India Limited Limited Corporate Relationship Corporate Relationship Department Department Listing Department Listing Department Phiroze Jeejeebhoy Phiroze Jeejeebh
Slide 2: Investor Presentation Q1 FY27
|GLAND| GLAND PHARMA Investor Presentation Q1 Q1 FY27 FY27 10 10 th th August August 2026 2026
Slide 3: Safe Harbour Statement
Safe Safe Harbour Harbour Statement Statement The The Presentation Presentation is is to to provide provide the the general general background background information information about about the the Company’s activities Company’s activities as as at at the the date date of of the the Presentation. Pr
Slide 4: Financial Highlights
GLAND Financial Highlights Financial Highlights
Slide 5: Consolidated P&L
Consolidated P&L Consolidated P&L ₹ Mn ?Mn Particulars Particulars Q1 FY27 Q1 FY26 YoY Q4 FY26 QoQ QoQ Revenue from Revenue from operations operations 18,003 18,003 15,056 15,056 20% 20% 17,428 17,428 3% 3% Other Income 612 575 575 6% 6% 1,115 1,115 -45% -45% Total Income Total Income 18,615 18,615
Slide 6: Consolidated Financial Highlights (1/3)
Consolidated Consolidated Financial Financial Highlights (1/3) Highlights (1/3) Revenue Revenue from from Operations Operations Gross Gross Profit 1 ) / Gross Profit*(1) Gross Profit Profit Margin 2 Margin*(2) ) (₹ Mn) (< (₹ Mn / %) (< 17,428 18,003 11,515 11,759 15,056 9,845 66% 65% 65% Q1 FY26 Q4
Slide 7: Consolidated Financial Highlights (2/3)
Consolidated Consolidated Financial Financial Highlights Highlights (2/3) (2/3) (1) Net Worth Net Worth (1) ROCE (2) //RONW ROCE RONW(3) (₹ Mn) (? (%) (%) RoCE RoNW 91,507 103,580 106,762 14% 15.0% 9% 11% 11% 12% 10.0% 11% 11% 8% 5.0% 0.0% FY25 FY26 Jun'26 FY25 FY26 Jun'26 Jun’26 Capital Capital Exp
Slide 8: Consolidated Financial Highlights (3/3)
Consolidated Consolidated Financial Financial Highlights Highlights (3/3) (3/3) Cash Cash and and Bank Bank Balances Balances // Net Net Cash (1) Cash (1) Cash Cash Flow from Operations Flow from Operations (₹ Mn) ■■Total Total Cash (₹ (? Mn) (? Net Cash 4,045 33,59 1 33,591 31 157 35,466 32,939 32,
Slide 9: Business Update
GLAND Business Update Business Update
Slide 10: Business-wise Revenue Break-up
Business-wise Business-wise Revenue Revenue Break-up Break-up ₹ Mn ?Mn Business Business Q1 FY27 Q1 FY26 YoY Q4 FY26 QoQ QoQ CDMO 8,915 8,915 7,411 20% 20% 8,059 8,059 11% 11% B2B* 9,088 9,088 7,645 7,645 19% 19% 9,369 9,369 -3% -3% Total Total 18,003 15,056 20% 20% 17,428 3% 3% Revenue Distribution
Slide 11: Business Updates
Business Updates Business Updates • *; •• R&D R&D Expenses: Expenses: Total Total R&D R&D expenses expenses were were ₹772 772 million million in in Q1 Q1 FY27, FY27, representing representing 4% 4% of consolidated revenue. of consolidated revenue. The The R&D R&D expenditure expenditure was was mai
Slide 12: Geographical Revenue
GLAND Geographical Geographical Revenue
Slide 13: US Market
US US Market Market ?₹ Mn Mn Revenue Contribution CDMO B2B B2B 32% YoY 48% YoY 27% YoY 2,653 7,571 7,157 9,807 9,810 2,236 5,649 1,794 7,443 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 US Filings Update US Contribution Business Update Q1FY27 Q1FY27 Cumulative Cumulative •
Slide 14: Europe Market
Europe Europe Market Market t₹MMn n Revenue Contribution CDMO CDMO B2B 20% YoY 20% YoY 6% YoY 36 38 3,814 3,954 3,791 3,916 3,302 3,267 23 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Europe Contribution Business Update • Volume expansion in existing products, including 22
Slide 15: Other Core Markets (Canada, Australia and New Zealand)
Other Other Core COPG Markets Markets (Canada, (Canada, Australia Australia and and New Zealand) New Zealand) ?₹ Mn Mn Revenue Contribution CDMO B2B B2B -28% YoY -45% YoY -11% YoY 739 363 376 314 335 588 534 274 199 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Other Core M
Slide 16: Rest of the World
Rest of the Rest of the World World t₹MMn n Revenue Contribution CDMO CDMO B2B 2% YoY -1% YoY 6% YoY 1,677 1,301 1,375 2,978 3,039 1,664 1,209 2,549 1,340 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 RoW Contribution Business Update • Growth seen across some of the key 17%
Slide 17: India
India India t₹MMn n Revenue Contribution CDMO CDMO B2B* 12% YoY 56% YoY -36% YoY 284 670 666 483 251 594 419 183 310 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 India Contribution Business Update • Growth seen in CDMO for certain products, 4% 4% including Huminsulin. Q1 Q
Slide 18: Thank You
iGiANPl GLAND PHARMA Thank You Thank You Investor Relations Corporate Office Sampath Sampath Kumar Kumar Pallerlamudi Pallerlamudi Gland Gland Pharma Pharma Limited Limited Company Company Secretary Secretary & & Compliance Compliance Officer Officer Plot Plot No. No. 11 11 & & 84, 84, TSIIC TSIIC P